Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
8.00
-0.08 (-0.99%)
At close: Jun 18, 2024, 4:00 PM
7.98
-0.02 (-0.25%)
After-hours: Jun 18, 2024, 7:59 PM EDT

Iovance Biotherapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2007
Cash & Equivalents
181.32238.1684.3172.8519.42
Upgrade
Short-Term Investments
164.98240.11426.18562.11293.11
Upgrade
Cash & Cash Equivalents
346.3478.28510.49634.96312.53
Upgrade
Cash Growth
-27.59%-6.31%-19.60%103.17%-33.29%
Upgrade
Receivables
0.150000
Upgrade
Inventory
10.370000
Upgrade
Other Current Assets
-48.970.84-2.541.143.96
Upgrade
Total Current Assets
307.85479.12507.96636.1316.49
Upgrade
Property, Plant & Equipment
176.55178.25169.92113.9219.23
Upgrade
Long-Term Investments
0091.5900
Upgrade
Goodwill and Intangibles
229.260000
Upgrade
Other Long-Term Assets
66.76.627.8718.448.93
Upgrade
Total Long-Term Assets
472.5184.87269.38132.3628.16
Upgrade
Total Assets
780.35663.98777.33768.46344.66
Upgrade
Accounts Payable
33.1226.627.3813.5115.57
Upgrade
Current Debt
7.7812.595.066.287.25
Upgrade
Other Current Liabilities
69.4152.356.7735.0716.27
Upgrade
Total Current Liabilities
110.3191.4989.254.8739.08
Upgrade
Long-Term Debt
68.0972.8666.4745.384.25
Upgrade
Other Long-Term Liabilities
17.350011.712.35
Upgrade
Total Long-Term Liabilities
85.4372.8666.4757.096.6
Upgrade
Total Liabilities
195.74164.34155.67111.9645.68
Upgrade
Total Debt
75.8685.4571.5351.6611.5
Upgrade
Debt Growth
-11.22%19.45%38.47%349.21%-
Upgrade
Retained Earnings
-2,012.38-1,568.34-1,172.45-830.19-570.61
Upgrade
Comprehensive Income
2.53-0.9-0.60.020.22
Upgrade
Shareholders' Equity
584.61499.64621.66656.5298.97
Upgrade
Net Cash / Debt
270.44392.83438.96583.3301.03
Upgrade
Net Cash / Debt Growth
-31.16%-10.51%-24.75%93.77%-35.75%
Upgrade
Net Cash Per Share
1.152.472.864.222.42
Upgrade
Working Capital
197.54387.63418.76581.23277.41
Upgrade
Book Value Per Share
2.493.144.054.752.40
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).